Lepu Biotech, a Shanghai immunotherapy company, raised $131 million in a series A financing led by Beijing healthcare investor Shiyu Capital. Lepu, a subsidiary of China medical device company Lepu Medical, was founded in 2018 to develop immunotherapies. According to press reports, the company has PD-1, PD-L1 and antibody-drug conjugate (ADC) candidates that have begun clinical trials. The company plans to use the capital to speed up its trial activity and build production facilities.
Source: China Biotoday
